BOCI Securities Limited: Upgrades Sino Biopharmaceutical (01801.HK) to a target price of 82 Hong Kong dollars and maintains a "buy" rating.

According to the Wisdom Financial APP, China International released a research report stating that Innovent Biologics (01801.HK) updated positive data on IBI363 at the ASCO conference. The bank has incorporated the future contribution of IBI363 into its forecast, and has raised the company's revenue forecast for 2025, 2026, and 2027 to 11.4 billion yuan, 14.2 billion yuan, and 17.9 billion yuan respectively. The target price has been raised from 56 Hong Kong dollars to 82 Hong Kong dollars, maintaining a "buy" rating.